Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

We'd be surprised if Champions Oncology, Inc. (NASDAQ:CSBR) shareholders haven't noticed that the Chief Strategy & Innovation Officer and Director, Philip Breitfeld, recently sold US$357k worth of stock at US$11.35 per share. Equally important, that sale actually reduced their holding by a full 100% which hardly makes us feel bullish about the stock.

Check out our latest analysis for Champions Oncology

Champions Oncology Insider Transactions Over The Last Year

In fact, the recent sale by Philip Breitfeld was the biggest sale of Champions Oncology shares made by an insider individual in the last twelve months, according to our records. That means that an insider was selling shares at below the current price (US$11.41). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. However, while insider selling is sometimes discouraging, it's only a weak signal. We note that the biggest single sale was 100% of Philip Breitfeld's holding.

Over the last year, we can see that insiders have bought 1.32k shares worth US$7.7k. But insiders sold 31.52k shares worth US$357k. All up, insiders sold more shares in Champions Oncology than they bought, over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Does Champions Oncology Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Champions Oncology insiders own about US$30m worth of shares. That equates to 21% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Do The Champions Oncology Insider Transactions Indicate?

An insider sold stock recently, but they haven't been buying. Zooming out, the longer term picture doesn't give us much comfort. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We're in no rush to buy! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Champions Oncology. To assist with this, we've discovered 3 warning signs that you should run your eye over to get a better picture of Champions Oncology.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

If you decide to trade Champions Oncology, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.